10 Biotech stocks bought by insiders

Insider buying is many times a good indicator if the future direction of a stock. After all, insiders know the most about their company and as such can usually estimate it's value. Let's take a look at biotech stocks bought by insider in the past year (min. market cap 300 million):

10. Incyte Corporation

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation.

Market Cap: $9.4 billion
Insider buying: 51.35%
Shares float: 150 million
Insider ownership: 0.8%
P/B: -

9. Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. 

Market Cap: $9.4 billion
Insider buying: 57.7%
Shares float: 145 million
Insider ownership: 0.5%
P/B: 6.5

8. PDL Biopharma

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases.

Market Cap: $1.5billion
Insider buying: 61.2%
Shares float: 160 million
Insider ownership: 0.4%
P/B: 7.3

7. Kindred Bioscences

They focus on the development of therapies for pets. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses.

Market Cap: $372
Insider buying: 61.5%
Shares float: 16
Insider ownership: 0.2%
P/B: 5.2%

6. Insys Therapeutics

The company isa a commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products.

Market Cap: $998 million
Insider buying: 66%
Shares float: 34 million
Insider ownership: 0.9%
P/B: 10

5. Synta Pharmaceuticals

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases.

Market Cap: $402 million
Insider buying: 68.4%
Shares float: 57 million
Insider ownership: 3.3%
P/B: 9.6

4. Cell Therapeutics

CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer.

Market Cap: $452 million
Insider buying: 69.7%
Shares float: 124 million
Insider ownership: 4.6%
P/B: 16.7

3. Repros Therapeutics

Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders in the United States.

Market Cap: $393 million
Insider buying: 76.3%
Shares float: 22.5 million
Insider ownership: 0.1%
P/B: 5.7%

2. Theravance

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement with Glaxo Group Limited (GSK). 

Market Cap: $3.3 billion
Insider buying: 81%
Shares float: 78 million
Insider ownership: 3.4%
P/B: 12.3

1. XOMA Corporation

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III studies for non-infectious uveitis. The company has various other products in it's pipeline.


Market Cap: $509.9 million
Insider buying: 136.7%
Shares float: 99.5 million
Insider ownership: 0.8%
P/B: 238.5

DOWNLOAD THE EXCEL SPREADSHEET FOR MORE INFORMATION